24-01-2021
Doctor leaflet
PotassiumOralSolution
Notto beinjected.
Must bediluted beforedrinking.
Dilutethedosein120ml(abouthalf aglass) ofwateror juiceand drinkslowly.
Composition
Activeingredient:Each5ml contains10mEqpotassium(1.4gpotassiumgluconateand
0.43gpotassiumcitrate).
Action
Potassiumis thepredominantcationwithinthecells (approximately150to160mEq/L) and
intracellular sodiumcontentis relativelylow.Highintracellular potassiumconcentrations are
necessaryfor numerous cellular metabolic processes.
Inextracellular fluid,sodiumpredominates andthepotassiumcontentis low(3.5-5mEq/L). A
membrane-boundenzyme,Na+K+ATPase,activelytransports or pumps sodiumoutand
potassiumintocells tomaintaintheseconcentrationgradients.Theintracellular to
extracellular potassiumgradientsare necessaryfor theconductionofnerveimpulsesin
suchspecializedtissues as theheart, brain,andskeletal muscle,andfor themaintenanceof
normal renal functionandacid-basebalance.
Indications
Potassiumoral solutionis indicatedfor thepreventionandtreatmentofhypokalemia.
Contraindications
Donotuseinpatientshypersensitivetoanyingredient.
Exceptunder special circumstances,donotuseinhyperkalemic patients,or inpatients
sufferingfromconditions predisposingtohyperkalemiasuchas:acutemetabolic acidosis,
adrenal insufficiency,acutedehydration,uncontrolleddiabetes mellitus,chronic renal failure
andextensivetissuebreakdown,becausefurther increases inserumpotassiummaycause
cardiacarrest.
Warnings
Cautionis warrantedinpatientssufferingfromsevere or prolongeddiarrhearesultingin
severe dehydration.Theloss offluids incombinationwithuseofpotassiumsupplements
maycauserenal toxicity,whichmayincreasetherisk ofhyperkalemia.Ifpotassium
supplementsare giveninthepresenceofdiarrhea,serumpotassiumlevels shouldbe
monitored.
Adelayinpassageofpotassiumsupplementsthroughthegastrointestinal tractcausedby
stricture or obstructionor peptic ulcer,maycauseor worsengastrointestinal irritation.
Potassiumsupplementsmayaggravatefamilial periodic paralysis or myotoniacongenita,
althoughsomepatientswithfamilial periodic paralysis mayrequire potassium
supplementation.
Careful monitoringofserumpotassiumis warrantedinpatientswithsevere or completeheart
block,especiallyindigitalizedpatients(seeDrugInteractions).
Cautionis warrantedinpatientssufferingfromesophageal compressionordelayedgastric
emptying.
UseinPregnancy:Studieshavenotbeendoneinanimals or inhumans.
FDA PregnancyCategoryC.
UseinBreastfeeding:Problems inhumans havenotbeendocumented.
UseintheElderly:Althoughappropriatestudiesontherelationshipofagetotheeffectsof
potassiumsupplementshavenotbeenperformedinthegeriatric population,nogeriatrics-
specific problems havebeensufficientlydocumentedtodate.However, elderlypatientsare
atgreater risk ofdevelopinghyperkalemiaduetoage-relatedchanges intheabilityofthe
kidneys toexcretepotassium.
UseinPediatrics:Appropriatestudiesontherelationshipofagetotheeffectsofpotassium
supplementshavenotbeenperformedinthepediatric population.However,nopediatrics-
specific problems havebeensufficientlydocumentedtodate.
AdverseReactions
Hyperkalemiasideeffectsare consideredrarewhenoral dosageforms ofpotassiumare
administeredtopatientshavingnormal renal function.Whenhyperkalemiais present,
symptoms include:severe muscleweakness,unusual tiredness,slowor irregular heartbeat,
confusion,numbness or tinglingofthehands,feetor lips,unexplainedanxiety,shortness of
breathor difficultbreathing.
Irritationofthealimentarytractmayoccur whenpotassiumpassageis delayedor is in
contactwithulcerous areas.Symptoms include:continuingabdominal or stomachpain,
cramping,or soreness,chestor throatpain,especiallywhenswallowing,stools containing
freshor digestedblood.
Thefollowingsideeffectsrequiremedical attentiononlyiftheycontinueor arebothersome:
diarrhea,nausea,stomachpain,discomfort, flatulenceor mildvomiting.(Thesesideeffects
occur more frequentlywhenthemedicationis nottakenwithfoodor is notdilutedproperly.)
Precautions
Patientsmustbewarnednottotakesalt substitutes or low-salt foods,unlessapprovedby
theirphysician,topreventexcess intakeofpotassium.
Adequaterenal functionis essential for therapywithpotassiumsupplements,sincethe
kidneys maintainnormal potassiumbalance.Monitoringofrenal function,potassiumserum
concentrations andECG is recommendedatperiodic intervals duringoral therapy.The
risk/benefit ofpotassiumsupplementshouldbeconsideredinanypatientwithahigher-than-
normal serumcreatinineconcentration.
Patientsmustbewarnednottobeginanystrenuous physical exercise,ifoutofcondition,to
preventpossibleexercise-inducedhyperkalemia.
DrugInteractions:
Digitalis glycoside,inthepresenceofheart block:potassiumsupplementsare not
recommendedfor concurrentuseinanydigitalizedpatientwithsevere or completeheart
block;however, ifpotassiumsupplementsmustbeusedtopreventor correcthypokalemiain
adigitalizedpatient,careful monitoringofserumpotassiumconcentrations is extremely
important.Abruptdiscontinuationofsupplemental potassiumtoapatientsuffering
concurrentpotassiumlosses,andalsoreceivingdigitalis preparations mayresult indigitalis
toxicity.
AmphotericinB,corticosteroidsespecially withsignificantmineralocorticoidactivity,
corticotropin(ACTH),gentamicin,penicillinsor polymyxinB:potassiumrequirementsmaybe
increasedinpatientsreceivingthesemedications duetorenal potassiumwasting.Close
monitoringofserumpotassiumis recommended.
Angiotensin-convertingenzymeinhibitors, beta-adrenergic blockingagents,potassium
sparingdiuretics, heparin,cyclosporin,non-steroidal anti-inflammatory drugs (NSAIDS):
concurrentusewithpotassiumsupplementsmayincreaseserumpotassiumconcentrations,
whichmaycausesevere hyperkalemiaandleadtocardiacarrest,especiallyinrenal
insufficiency.
Thiazidediuretics:there isanincreasedrisk ofhyperkalemiawhenapotassium-wasting
diuretic is discontinuedafter concurrentusewithapotassiumsupplement.
Low-salt milk,salt substitutes,potassium-containingmedications:concurrentusewith
potassiumsupplementsmayincreaseserumpotassiumconcentrations,whichmaycause
severe hyperkalemiaandleadtocardiacarrest,especiallyinrenal insufficiency.Mostsalt
substitutes containsubstantial amountsofpotassium(low-salt milk maycontainpotassium
upto60mEq/L).
Bloodfrombloodbank:bloodfrombloodbank maycontainpotassiumupto30mEq/Lof
plasmaor upto65mEq/Lofwholebloodwhenstoredfor more than10days.
Parenteral calciumsalts:potassiumsupplementsshouldbeusedcautiouslyinpatients
receivingparenteral calciumsalts becauseofthedanger ofprecipitatingcardiacarrhythmias.
Exchangeresins,sodiumcycle,suchas sodiumpolystyrenesulfonate:whether these
medications are administeredorallyor rectally,serumpotassiumconcentrations are reduced
bysodiumreplacementofthepotassium;fluidretentionmayoccur insomepatientsbecause
oftheincreasedsodiumintake.
Insulinor sodiumbicarbonate:concurrentuseofthesemedications withpotassium
decreases serumpotassiumconcentrations bypromotingashiftofpotassiumionintothe
cells.
Laxatives:chronic useor overuseoflaxatives mayreduceserumpotassiumconcentrations
bypromotingexcessivepotassiumloss fromtheintestinal tract.
Anticholinergics or other medications withanticholinergic activity:concurrentusemay
increaseseverityofgastrointestinal lesions producedbypotassiumchloridealone.If
symptoms develop,patientsshouldbecarefullymonitoredendoscopicallyfor evidenceof
lesions.
Dosageand Administration
Each5ml PotassiumOral Solutioncontains10mEqpotassium.
Cautionmustbeobservedintheattempttocorrecthypokalemiainorder toavoid
overcompensationandaresultanthyperkalemiawithaccompanyingcardiacarrhythmias
Adults:theusual adult andadolescentdoseis 20mEqofpotassium(10ml)dilutedin120
ml(abouthalf aglass)ofcold wateror juicetwotofour times aday.Adjustthedoseas
neededandtolerated.Donotexceed100mEqofpotassiumaday.
Pediatric:theusual pediatric doseis 20-40mEqofpotassiumper square meter ofbody
surfaceor 2-3mEqper kgofbodyweightaday,administeredindivideddoses andmust be
welldiluted inwateror juice.
This medicationmustbetakenwithor immediatelyafter food,and,after dilution,shouldbe
sippedslowly.
Thenormal adult concentrationofserumpotassiumis 3.5-5mEq/Lwith4.5mEqoftenbeing
usedfor areferencepoint.Potassiumconcentrations exceeding5.5mEq/Lare dangerous
becauseofpossibleinitiationofcardiacarrhythmias.(Normal potassiumconcentrations tend
tobehigher inneonates [7.7mEq/L]thaninadults.)
Serumpotassiumconcentrations donotnecessarilyindicatethetruebodypotassium
content.AriseinplasmapH (alkalosis)andchronic acidosis maydecreaseplasma
potassiumconcentrationbypromotingpotassiumexcretionandincreasetheintracellular
potassiumconcentration.Conversely,adecreaseinbloodpH (acuteacidosis)cancausean
increaseinserumpotassiumbyinhibitingpotassiumexcretion.However, it isnecessaryto
attempttorestore serumpotassiumtonormalinfamilial periodic paralysis, eventhough
there isnototal bodypotassiumdepletion.(It maybeadvisabletomonitor serumpH
periodicallyduringtreatment.)
Overdosage
Treatmentofhyperkalemia:
Ifappropriate,discontinuebloodproducts,foodsandmedicationthatcontain
potassium,as wellas ACEinhibitors, betablockingagents,nonsteroidal anti-
inflammatorydrugs,heparin,cyclosporinandpotassium-sparingdiuretics.
Administer 10%dextrosecontaining10to20units ofinsulinper liter atarateof
300to500ml ofsolutionper hour. This will facilitateashiftofpotassiumintothecells.
Correctanyexistingacidosis with50mEqintravenous sodiumbicarbonateover 5
minutes.Thedosemayberepeatedin10to15minutes ifneeded.This willfacilitatea
shiftofpotassiumintothecells.
Administer acalciumsalt (calciumgluconate,0.5to1gram,over a2minuteperiod)
toantagonizethecardiotoxic effectsinpatientswhoseECG showabsentPwaves,or
abroadQRScomplex,andwhoare notreceivingdigitalis glycosides.Doses maybe
repeatedafter 2-minuteintervals.
Useexchangeresins toremoveexcess potassiumfromthebodybyadsorption
and/or exchangeofpotassium.Theoral doseofsodiumpolystyrenesulfonateis 20to
50grams oftheresindissolvedin100to200ml of20%sorbitol. Thedosemaybe
givenevery4hours uptofour or fivedailydoses until potassiumlevels return to
normal. Itmayalsobegivenas aretentionenemabymixing8grams ofsodium
polystyrenesulfonateand50grams ofsorbitol in200ml ofwater. Theretention
enemaexchanges potassiumfaster thantheoral sodiumpolystyrenesulfonate.
Usehemodialysis or peritoneal dialysis toreduceserumpotassiumconcentrations.
This maybenecessaryinpatientswithrenalfunctionimpairment.
Ascertainadequateurineoutputand,ifnotcontraindicatedbytheclinical condition
ofthepatient,maintainahighurineoutputwithnormal salinesolutions andloop
diuretics.
Cautionmustbeobservedwhentreatinghyperkalemiainadigitalizedpatient,sincerapid
reductionofserumpotassiumconcentrations mayinducedigitalis toxicity.
List ofexcipients
Ethanol,citric acidanhydrous,sodiumcyclamate,saccharinsodium,tutti frutti flavor,methyl
hydroxybenzoate,propyl hydroxybenzoate,purifiedwater.
PharmaceuticalPrecautions
Store below25 ˚C.
After firstopening,themedicinecouldbeusedfor6months.
Presentation
Bottlecontaining200ml.
RafaLaboratoriesLtd.,P.O.Box405,Jerusalem9100301
עעבקנהז ןולע טמרופ " ודילע רשואוקדבנונכותותואירבהדרשמ י .